Anyone who has been considering an investment in $ATAI (+1,91 %) for some time could perhaps take advantage of the setback today. Haven't found anything except the approval of the takeover of Psytech.

Psychedelics boom ahead? Study forecasts growth of over 12% p.a. by 2030 - these shares are in focus

https://www.wallstreet-online.de/nachricht/20122544-psychedelika-boom-voraus-studie-prognostiziert-wachstum-12-p-a-2030-aktien-stehen-fokus

Let's see where the journey takes us 😉 I actually wanted to join in June, but didn't dare 👎

$ATAI (+1,91 %) and Beckley Psytech Limited have announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to BPL-003 (mebufotenine benzoate) nasal spray for adult patients with treatment-resistant depression (TRD). The BTD is awarded to accelerate the development of drugs that target serious or life-threatening conditions and where initial clinical data indicate that the drug may show a significant improvement on one or more clinically relevant endpoints over existing therapies. The award facilitates collaboration with the FDA and has the potential to accelerate development timelines and regulatory reviews.

I am delighted for my portfolio, of course, but above all for the people who may soon be helped.

https://de.marketscreener.com/boerse-nachrichten/atai-life-sciences-n-v-und-beckley-psytech-us-fda-erteilt-bpl-003-den-status-als-breakthrough-th-ce7d5adcd18bf722

atai Life Sciences: Innovations ($ATAI (+1,91 %) ) in the field of psychedelic therapies - Current successes and developments

1. successful phase 2b study on BPL-003 (5-MeO-DMT nasal spray)

On July 1, 2025 atai Life Sciences and Beckley Psytech published the topline topline results of the Phase 2b study of on BPL-003 in treatment-resistant depression. Both doses tested (8 mg and 12 mg) showed a statistically significant and clinically meaningful reduction in depression symptoms compared to a very low compared to a very low control dose - as early as on the first day day after administration, with a sustained effect until week 8. only 90 minutes after the dose discharge - a significant advance over previous psychedelic therapies with longer monitoring.stocktitan.netstatnews.com+12globenewswire.com+12ir.atai.life+12

These successes now allow the planning of Phase 3 trialsand the strategically agreed merger with Beckley Psytech can proceed to a shareholder vote in the next steps.globenewswire.com

2nd financing round: USD 50 million private placement

Also on July 1, 2025 atai announced a successful private placement in the amount of USD 50 million private placement. The round was jointly led by Ferring Ventures and Apeiron Investment Group; further investments were made by Ally Bridge Group and ADAR1. The funds will be used to finance general corporate objectives, to strengthen working capital and to further develop the clinical programs.insidermonkey.com+8nasdaq.com+8stocktitan.net+8

3. market reactions & analyst assessment

Following the publication of the trial results and the financing, the market reacted very positively:

• The share price rose around 27 % in pre-market trading.ainvest.com
• Canaccord Genuity raised its price target from USD 11 to USD 12 and confirmed its buy recommendation.insidermonkey.com
• H.C. Wainwright raised the price target from USD 10 to USD 15 with a "buy" rating.ir.atai.life+15insidermonkey.com+15insidermonkey.com+15
• Investors were inspired by the prospect of a new, more accessible psychedelic therapy, especially with a short clinical presence.ainvest.com+5barrons.com+5ft.com+5

Outlook

atai Life Sciences is on track with the progress of the BPL-003 program program, supported by solid financial resources and positive market sentiment. The planned merger with Beckley Psytech - subject to shareholder approval - is expected to further strengthen the company's profile and capabilities.

https://youtu.be/DKsGx8Ssu-0?si=4pYu_VlFoC3QXhM_

who wants with text https://geldschnurrbart.de/

$ATAI (+1,91 %)